Mauro G.
- Country
- Italy
- Department
- Urologia
Research Overview
- Phase III Randomized Study of Serenoa repens (Permixon) for Reducing Chronic Prostatic Inflammation and Re‑biopsy Need in Men with Benign Prostatic Hypertrophy.
- Evaluation of Padeliporfin Vascular Targeted Photodynamic Therapy in Low-Grade Upper Tract Urothelial Carcinoma: A Phase 3 Multicenter Study
- Evaluation of Intravesical ONCOFID-P-B (Paclitaxel Obaluronate) in BCG-Unresponsive Carcinoma in Situ of the Bladder with or without Ta-T1 Papillary Disease
Data & Insights
Has run more than one trial at 4 of 37 partner sites.
Specializations
Urological Oncology
The investigator specializes in treating complex urological cancers, with particular expertise in upper tract urothelial cancer (UTUC) and innovative therapeutic approaches using vascular targeted photodynamic therapy.
- Low-grade UTUC management
- Photodynamic therapy applications
- Minimally invasive treatments
Their research encompasses treatments targeting tumors in the calyces, renal pelvis, and ureter regions.
Bladder Cancer Research
The investigator focuses on advanced treatments for bladder carcinoma in situ, particularly in cases where conventional therapies have proven ineffective.
- BCG-unresponsive bladder cancer
- Intravesical therapy development
- Novel therapeutic compounds
Their work includes evaluation of innovative intravesical treatments for resistant bladder cancer cases.
Therapeutic Innovation
The investigator pursues advancement in targeted cancer therapies, specifically focusing on novel drug delivery systems and treatment methodologies for urological cancers.
- Alternative treatment strategies
- Treatment-resistant cancers
- Therapeutic response assessment
Their research involves evaluating antitumor activity and treatment efficacy in complex urological cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.